Host: John J. Russell, MD

Guest: James Wetmore, MD

Guest: Michael Germain, MD

Guest: Barbara Weis Malone, RN

Guest: Mike Spigler

Secondary hyperparathyroidism (HPT) refers to the excessive secretion of parathyroid hormone (PTH) by the parathyroid glands in response to decreased renal function and impaired mineral metabolism.1,2 Secondary HPT often occurs in advanced chronic kidney disease (CKD) and may be initially silent and asymptomatic.2 As a result, it is frequently underdiagnosed and undertreated.1,3 Management of secondary HPT and advanced CKD requires the coordinated efforts of a multidisciplinary team of healthcare professionals.2 Host Dr. John Russell welcomes a diverse panel, including Dr. James Wetmore, Dr. Michael Germain, registered nurse Barbara Weis Malone and Mike Spigler of the American Kidney Fund®. Tune in as we discuss the unique role each team member plays in the clinical management of secondary HPT, as well as recommended best practices to help synchronize this approach and optimize care for these patients. 1 Joy MS et al. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. J Manag Care Pharm. 2007; Jun;13(5)397-411. 2 Tomasello S. Secondary Hyperparathyroidism and Chronic Kidney Disease. Diabetes Spectr. 2008; Jan;21(1)19-25. 3 National Kidney Foundation. Parathyroid Hormone and Secondary Hyperparathyroidism in Chronic Kidney Disease. Available at: www.kidney.org/sites/default/files/02-10-4899_GB_SHPT-PTH_v8.pdf. Accessed May 17, 2017. USA-416-062150